Complete APRE Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
APRE DCF Analysis
APRE (Aprea Therapeutics, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $583.2K | $1.5M | $1.9M | $2.3M | $2.9M | $3.7M | $4.6M |
| Revenue Growth % | - | Infinity% | 157.6% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| EBIT | $38.2M | $-15.5M | $-14.3M | $93.9K | $117.4K | $146.7K | $183.4K | $229.3K |
| EBIT Margin % | 0.0% | -2652.8% | -953.0% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $28.6M | $-11.6M | $-10.7M | $70.4K | $88.0K | $110.1K | $137.6K | $172.0K |
| NOPAT Margin % | Infinity% | -1989.6% | -714.8% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $0 | $93.1K | $15.5K | $159.6K | $189.5K | $225.0K | $267.2K | $317.3K |
| Capex / Revenue % | NaN% | 16.0% | 1.0% | 8.5% | 8.1% | 7.7% | 7.3% | 6.9% |
| Depreciation | $186.4K | $7.1K | $22.3K | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| D&A / Revenue % | Infinity% | 1.2% | 1.5% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Change in NWC | $-22.3M | $-8.8M | $2.1M | $18.8K | $23.5K | $29.3K | $36.7K | $45.9K |
| NWC Change / Revenue % | -Infinity% | -1511.7% | 138.4% | 1.0% | 1.0% | 1.0% | 1.0% | 1.0% |
| Unlevered FCF | $51.1M | $-2.9M | $-12.8M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| UFCF % Chg. | - | -105.6% | -346.0% | Infinity% | NaN% | NaN% | NaN% | NaN% |
| FCF / Revenue % | Infinity% | -492.6% | -852.7% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Discount Factor | - | - | - | 0.899 | 0.808 | 0.726 | 0.653 | 0.587 |
| Present Value of FCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| Sum of PV of UFCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.8% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.1% |
| Risk Free Rate | 4.29% |
| Market Risk Premium | 4.3% |
| Beta | 1.61 |
| Cost of Equity | 11.3% |
| Total Debt | $0 |
| Market Cap | $9.5M |
| Total Capital | $9.5M |
| Debt Weighting | 0.0% |
| Equity Weighting | 100.0% |
| WACC | 11.3% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $InfinityB |
| Terminal Value | $InfinityB |
| PV of Terminal Value | $InfinityB |
| Cumulative PV of UFCF | $InfinityB |
| Net Debt | $-22.8M |
| Equity Value | $InfinityB |
| Shares Outstanding | 5.5M |
| Implied Share Price | $InfinityB |
| Current Share Price | $2 |
| Implied Upside/(Downside) | +Infinity% |
Valuation Summary
$Infinity
Implied Price
$1.72
Current Price
+Infinity%
Upside/Downside
11.3%
WACC
APRE Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 7 peer companies in Healthcare
P/E Ratio
$-23.11
-1443.8%
Peer Median: 9.8x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$0.60
-65.1%
Peer Median: 4.3x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for APRE's business model and current situation.
Multiple Comparison
| Multiple | APRE Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.7x | 9.8x | 9.8x | -107.4% | Undervalued |
| EV/EBITDA | -Infinityx | 0.0x | 0.0x | -Infinity% | Undervalued |
| P/S Ratio | 12.4x | 4.3x | 5.6x | 186.7% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.01B | 0.0x | 0.0x | 59.9x | |
| $0.01B | 9.8x | -1.4x | 309.8x | |
| $0.01B | 0.0x | 0.0x | 0.2x | |
| $0.01B | 0.0x | 0.0x | 12.4x | |
| $0.01B | 0.0x | 0.0x | 4.3x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 0.0x |